207 related articles for article (PubMed ID: 24952250)
1. Primary mediastinal large B-cell lymphoma.
Dabrowska-Iwanicka A; Walewski JA
Curr Hematol Malig Rep; 2014 Sep; 9(3):273-83. PubMed ID: 24952250
[TBL] [Abstract][Full Text] [Related]
2. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis.
Shah NN; Szabo A; Huntington SF; Epperla N; Reddy N; Ganguly S; Vose J; Obiozor C; Faruqi F; Kovach AE; Costa LJ; Xavier AC; Okal R; Kanate AS; Ghosh N; Kharfan-Dabaja MA; Strelec L; Hamadani M; Fenske TS; Calzada O; Cohen JB; Chavez J; Svoboda J
Br J Haematol; 2018 Feb; 180(4):534-544. PubMed ID: 29265182
[TBL] [Abstract][Full Text] [Related]
3. The role of FDG-PET imaging as a prognostic marker of outcome in primary mediastinal B-cell lymphoma.
Nagle SJ; Chong EA; Chekol S; Shah NN; Nasta SD; Glatstein E; Plastaras JP; Torigian DA; Schuster SJ; Svoboda J
Cancer Med; 2015 Jan; 4(1):7-15. PubMed ID: 25205600
[TBL] [Abstract][Full Text] [Related]
4. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factors in 41 consecutive Asian patients.
Tai WM; Quah D; Yap SP; Tan SH; Tang T; Tay KW; Koo YX; Tao M; Quek R; Lim ST
Leuk Lymphoma; 2011 Apr; 52(4):604-12. PubMed ID: 21261504
[TBL] [Abstract][Full Text] [Related]
5. A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy.
Binkley MS; Hiniker SM; Wu S; Natkunam Y; Mittra ES; Advani RH; Hoppe RT
Leuk Lymphoma; 2016; 57(3):604-8. PubMed ID: 26159046
[TBL] [Abstract][Full Text] [Related]
6. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience.
Savage KJ; Al-Rajhi N; Voss N; Paltiel C; Klasa R; Gascoyne RD; Connors JM
Ann Oncol; 2006 Jan; 17(1):123-30. PubMed ID: 16236753
[TBL] [Abstract][Full Text] [Related]
7. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
8. R-CHOP without radiation in frontline management of primary mediastinal B-cell lymphoma.
Messmer M; Tsai HL; Varadhan R; Swinnen LJ; Jones RJ; Ambinder RF; Shanbhag SP; Borowitz MJ; Wagner-Johnston N
Leuk Lymphoma; 2019 May; 60(5):1261-1265. PubMed ID: 30656983
[TBL] [Abstract][Full Text] [Related]
9. Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial.
Pytlík R; Belada D; Kubáčková K; Vášová I; Kozák T; Pirnos J; Bolomská I; Matuška M; Přibylová J; Campr V; Burešová L; Sýkorová A; Berková A; Klener P; Trněný M;
Leuk Lymphoma; 2015 Jan; 56(1):57-64. PubMed ID: 24628294
[TBL] [Abstract][Full Text] [Related]
10. End of treatment FDG-PET in primary mediastinal B-cell lymphoma treated with R-chemotherapy: Prognostic indicator and implications for consolidation radiotherapy.
Freitas AC; Carvalho IP; Esteves S; Salgado L; Gomes da Silva M
Eur J Haematol; 2022 Feb; 108(2):118-124. PubMed ID: 34599779
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Role of Pre-Radiation Therapy (18)F-Fluorodeoxyglucose Positron Emission Tomography for Primary Mediastinal B-Cell Lymphomas Treated with R-CHOP or R-CHOP-Like Chemotherapy Plus Radiation.
Filippi AR; Piva C; Levis M; Chiappella A; Caracciolo D; Bellò M; Bisi G; Vitolo U; Ricardi U
Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1239-43. PubMed ID: 27130796
[TBL] [Abstract][Full Text] [Related]
12. Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease.
Soumerai JD; Hellmann MD; Feng Y; Sohani AR; Toomey CE; Barnes JA; Takvorian RW; Neuberg D; Hochberg EP; Abramson JS
Leuk Lymphoma; 2014 Mar; 55(3):538-43. PubMed ID: 23734654
[TBL] [Abstract][Full Text] [Related]
13. Targeting the intratumor heterogeneity in PMBL.
Ritz O; Möller P; Ushmorov A
Cell Cycle; 2014; 13(15):2317-8. PubMed ID: 25483178
[No Abstract] [Full Text] [Related]
14. Dose-adjusted EPOCH-R is not superior to sequential R-CHOP/R-ICE as a frontline treatment for newly diagnosed primary mediastinal B-cell lymphoma: Results of a bi-center retrospective study.
Morgenstern Y; Aumann S; Goldschmidt N; Gatt ME; Nachmias B; Horowitz NA
Cancer Med; 2021 Dec; 10(24):8866-8875. PubMed ID: 34816617
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of clinical characteristics and
Liu Y; Jiang J; Liu L; Wang Z; Yu B; Xia Z; Zhang Q; Ji D; Liu X; Lv F; Hong X; Song S; Cao J
J Int Med Res; 2022 Jan; 50(1):3000605211063027. PubMed ID: 35001690
[TBL] [Abstract][Full Text] [Related]
16. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography.
Pinnix CC; Dabaja B; Ahmed MA; Chuang HH; Costelloe C; Wogan CF; Reed V; Romaguera JE; Neelapu S; Oki Y; Rodriguez MA; Fayad L; Hagemeister FB; Nastoupil L; Turturro F; Fowler N; Fanale MA; Nieto Y; Khouri IF; Ahmed S; Medeiros LJ; Davis RE; Westin J
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):113-21. PubMed ID: 25863759
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma.
Ferrara F; Ravasio R
Clin Drug Investig; 2008; 28(1):55-65. PubMed ID: 18081361
[TBL] [Abstract][Full Text] [Related]
18. Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma.
Lisenko K; Dingeldein G; Cremer M; Kriegsmann M; Ho AD; Rieger M; Witzens-Harig M
BMC Cancer; 2017 May; 17(1):359. PubMed ID: 28532396
[TBL] [Abstract][Full Text] [Related]
19. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
[TBL] [Abstract][Full Text] [Related]
20. Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: Results from a monoinstitutional cohort analysis of long-term survivors.
De Sanctis V; Alfò M; Di Rocco A; Ansuinelli M; Russo E; Osti MF; Valeriani M; Minniti G; Grapulin L; Musio D; Bracci S; Spagnoli A; Moleti ML; Tombolini V; Martelli M
Hematol Oncol; 2017 Dec; 35(4):554-560. PubMed ID: 28078727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
